⚙
AI-generated deep summary
by claude@2026-07, 2026-07-04
· read from full text
ⓘ
This study investigated whether neutrophils from people with cystic fibrosis functionally express CFTR and how the CFTR modulator combination elexacaftor, tezacaftor, and ivacaftor (ETI/Trikafta) affects CFTR trafficking and neutrophil antimicrobial functions. Using neutrophils from patients with CF, the authors found that CF neutrophils express CFTR and that ETI modifies subcellular CFTR trafficking, lowers intracellular chloride levels consistent with CFTR-dependent chloride efflux, and reestablishes intracellular antimicrobial killing by potentiating NADPH oxidase activity and increasing neutrophil extracellular trap (NET) formation. The main limitation is that the work focuses on mechanistic cellular findings in neutrophils rather than directly establishing the in vivo clinical impact of these pathways for individual patients. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Abstract
ABSTRACT Cystic fibrosis ( CF ), a common genetic disease, is caused by a defective CF-transmembrane conductance regulator ( CFTR ). People with CF ( pwCF ) are prone to develop infections by opportunistic pathogens, including Burkholderia cenocepacia , leading to chronic inflammation and lung function loss. Neutrophils, the most abundant cells in the chronically inflamed lungs of pwCF, release granular proteins and oxidative products that contribute to tissue damage. The CFTR modulators are a new treatment for pwCF aiming to correct the subcellular location and function of the CFTR ion channel. The triple modulator combination of Elexacaftor, Tezacaftor, and Ivacaftor ( ETI ) or Trikafta ® has significantly improved clinical symptoms and overall provided a better quality of life for pwCF. The mechanism by which the CFTR modulators help to restore the antimicrobial functions of neutrophils is unknown. The present study demonstrates that neutrophils functionally express CFTR and reveals how ETI modifies subcellular CFTR trafficking in CF neutrophils. In addition, ETI treatment reduces intracellular chloride levels in human neutrophils, indicating activation of CFTR-dependent chloride efflux (outflow). Finally, ETI treatment also reestablished the intracellular antimicrobial killing of CF neutrophils by potentiating NADPH oxidase activity and producing Neutrophil Extracellular Traps (NETs). Together, our findings suggest that CFTR has an essential role in controlling neutrophil functions and that the CFTR modulators improve the health of pwCF by restoring the antimicrobial functions of CF neutrophils. Abstract Figure Graphical abstract. (A ) The F508del defective CFTR protein cannot reach the plasma membrane in CF neutrophils, which increases the intracellular concentrations of Cl − ions, and allows other ions to be internalized, including Na + and Ca 2+ . This ionic imbalance affects the NADPH oxidase, leading to a reduced preactivation response and consequently impacting NADPH oxidase-dependent antimicrobial mechanisms, including intracellular antimicrobial killing and NETosis. (B) Treating with ETI restores the CFTR expression in the plasma membrane of CF neutrophils, increasing the Cl − efflux and regulating the intracellular levels of Na + and Ca 2+ , leading to correcting the NADPH oxidase, which results in potentiating the intracellular antimicrobial killing and NETosis. Biorender TM tools generated the images.
Full text
2,299 characters
· extracted from
oa-doi-fallback
· click to expand
ABSTRACT
Cystic fibrosis (CF), a common genetic disease, is caused by a defective CF-transmembrane conductance regulator (CFTR). People with CF (pwCF) are prone to develop infections by opportunistic pathogens, including Burkholderia cenocepacia, leading to chronic inflammation and lung function loss. Neutrophils, the most abundant cells in the chronically inflamed lungs of pwCF, release granular proteins and oxidative products that contribute to tissue damage. The CFTR modulators are a new treatment for pwCF aiming to correct the subcellular location and function of the CFTR ion channel. The triple modulator combination of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) or Trikafta® has significantly improved clinical symptoms and overall provided a better quality of life for pwCF. The mechanism by which the CFTR modulators help to restore the antimicrobial functions of neutrophils is unknown. The present study demonstrates that neutrophils functionally express CFTR and reveals how ETI modifies subcellular CFTR trafficking in CF neutrophils. In addition, ETI treatment reduces intracellular chloride levels in human neutrophils, indicating activation of CFTR-dependent chloride efflux (outflow). Finally, ETI treatment also reestablished the intracellular antimicrobial killing of CF neutrophils by potentiating NADPH oxidase activity and producing Neutrophil Extracellular Traps (NETs). Together, our findings suggest that CFTR has an essential role in controlling neutrophil functions and that the CFTR modulators improve the health of pwCF by restoring the antimicrobial functions of CF neutrophils.
Competing Interest Statement
Conflicts of interest: Dr. McCoy reports grants from 4D Molecular Therapeutics, AbbVie, Aridis Pharmaceuticals, Armata Pharmaceuticals, Boehringer Ingelheim, Cyst-ic Fibrosis Foundation, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Insmed, Lau-rent Pharmaceuticals, Novoteris, Proteostasis Therapeutics, Savara, Translate Bio, Vertex Pharmaceuticals, all outside the submitted work. All the related funding is given to her institution of employment for the above-listed entities to support research trials. She received no direct money, and none of these relationships conflict with this manu-script. The other authors declare no conflict of interest.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.